



## **Aastrom Biosciences to Present At Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference**

ANN ARBOR, Mich., Oct 30, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Gerald D. Brennan, Vice President, Administrative and Financial Operations and Chief Financial Officer and Elmar R. Burchardt, MD, PhD, Vice President, Medical Affairs, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The conference will be held November 5-7th at The New York Palace Hotel in New York City, NY. Mr. Brennan and Dr. Burchardt will present at 10:15 a.m. (Eastern Time), on Monday, November 5, 2007.

A live webcast of Aastrom's presentation can be accessed by logging onto the web at <http://www.wsw.com/webcast/rrshq12/astm>. A replay of the presentation will be archived for 90 days, at the same site.

For more information, please visit the conference website at: <http://www.rodmanandrenshaw.com/conferences?id=6>.

About Aastrom Biosciences, Inc.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The company's proprietary Tissue Repair Cell (TRC) Technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting bone, vascular, cardiac, and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC Technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the company has a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a vascular regeneration product in clinical development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), and preclinical research programs targeting unmet needs in cardiac and neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA. For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com). (astmc)

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials and activities and anticipated timing of clinical events, product development objectives, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "anticipated," "planned," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are potential patient accrual difficulties, clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

The Aastrom Biosciences, Inc. logo is available at <http://www.primenewswire.com/newsroom/prs/?pkgid=3663>

This news release was distributed by PrimeNewswire, [www.primenewswire.com](http://www.primenewswire.com)

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.

Investor Relations Department

Kris M. Maly

(734) 930-5777

Cameron & Associates

(Investors)

Kevin McGrath

(212) 245-4577

Berry & Company

(Media)

Stephen Zoegall

(212) 253-8881

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX